Alejandro Dorenbaum, CMO of Reneo Pharmaceuticals Discusses Clinical-Stage Therapies
In this episode we will be talking to Alejandro Dorembaum, CEO of Reneo Pharmaceuticals. Alex discusses how the company is developing drugs for patients with rare mitochondrial diseases a high unmet disease with no current treatments available. Their lead candidate Mavodelpar has recently completed enrolment for their STRIDE clinical trial study.
Reneo Pharmaceuticals: https://reneopharma.com/
Reneo is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs.
Reneo Pharma: https://reneopharma.com/
Reneo is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs.
LinkedIn: Alejandro Dorenbaum
https://www.linkedin.com/in/alejandro-alex-dorenbaum-m-d-b01a6ab/
Create your
podcast in
minutes
It is Free